Free Trial Free TrialFree Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Canada Cannabis fees rise in line with inflation…
  • Kentucky - United States Bill to ban delta-8 sales to under-21s land on governor’s desk…
  • Oklahoma - United States House approves extension to Medical Marijuana Authority’s powers…
  • Spain Podemos and allies call for hemp regulation…
  • Belgium Positive notifications list updated…
  • Bulgaria Industrial cannabis THC limit could be increased…
  • Germany Public hearing held over decriminalising cannabis…
  • Afghanistan Decree issued to ban hemp cultivation…
  • United States Bills on hemp and CBD regulatory framework reintroduced in the House…
  • Maryland - United States Bill updating definition of hemp and hemp product passes Senate…
  • Kentucky - United States Medical cannabis bill passes Senate and head to House…
  • Luxembourg Council of State issues opinion over cannabis legislation…
View all
News analysis

Trump nominee Hahn unlikely to change much as FDA commissioner

Written by || 6th November 2019 || News analysis | Policy and Politics | Regulation and legislation | North America United States

Little is expected to change at the US FDA in terms of CBD or cannabis policy if president Donald Trump’s nominee Stephen Hahn is approved as commissioner, according to sources contacted by CBD-Intel ...

Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Email us

Related contents
FDA wades in with guidance on CBD – and warnings over ‘deceptive’ claims
More regulatory doubts over CBD in US as FDA commissioner steps down
FDA jurisdiction still unchallenged – but industry presses for clarity

CannIntelligence.com provides independent, in-depth regulatory and market data and intelligence for the global cannabis and cannabinoid sector.

© 2023 Tamarind Media Limited (T/A CannIntelligence)
CannIntelligence does not provide legal, strategic or investment advice. Tamarind Media Limited, the publisher of CannIntelligence, does not accept any liability or responsibility for information or views published.